Teleflex’s UroLift shows positive patient experience results in published study

Teleflex announced that a new peer-reviewed study in the Nature journal Prostate Cancer and Prostatic Diseases reinforces the position of the UroLift System as “the gold standard” in minimally invasive surgical treatment for benign prostatic hyperplasia – BPH -, or enlarged prostate. This first-of-its-kind study directly compares and analyzes outcomes in over 40,000 real-world BPH patients by applying a consistent definition of retreatment across the leading BPH treatments. Results suggest that within one year of BPH surgery, 1 in 20 patients may require retreatment regardless of whether they receive a transurethral resection of the prostate, GreenLight photoselective vaporization of the prostate, Rezm water vapor thermal therapy or UroLift System prostatic urethral lift; rates are not statistically different. At five years, retreatment was lowest for TURP and statistically similar between GreenLight PVP and the UroLift System. The retreatment rate for UroLift PUL is comparable to published controlled trial rates, thereby underscoring and demystifying the durability of the UroLift System. The study also provides a new way to assess and view complications following BPH surgery. At one-year procedural complications were lowest following the UroLift System – 15% – and highest following Rezm WVTT – 26% -. The average time to the first complication was the longest for the UroLift PUL.